District court denies preliminary injunctions by drug companies in challenges to Maine’s 340B contract pharmacy law
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges against the state’s law protecting 340B pricing for contract pharmacy arrangements. In particular, the court held that “Plaintiffs have failed to establish that they will likely succeed on the merits of their preemption, commerce clause, takings, [and] vagueness claims.”
The AHA, 340B Health, the Maine Hospital Association and the American Society of Health-System Pharmacists filed amicus briefs Sept. 11 and Sept. 15 opposing the preliminary injunctions. The AHA has opposed similar challenges by drug companies in multiple states.
Related News Articles
Headline
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B…
Headline
The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program because “a rebate mechanism of any kind…
Headline
The AHA and others April 17 filed an amicus brief requesting the U.S. Court of Appeals for the 4th Circuit grant en banc review of a panel decision that…
Headline
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…
Headline
The U.S. District Court for the District of Columbia March 31 vacated a Health Resources and Services Administration policy instituted in 2013 that restricted…
Headline
The U.S. Court of Appeals for the 4th Circuit March 31 upheld a preliminary injunction issued by the U.S. District Court for the District of West Virginia…